سعر انفاركا 100مجم 30 قرص 2022

Infarca 100 mg film-coated tablets (pack of 30, 3 strips of 10): cilostazol, a phosphodiesterase-3 inhibitor antiplatelet agent, listed in Egypt under Debeiky > Zad.

• Improvement of ischemic symptoms (ulceration, pain and coldness of the extremities) in chronic arterial occlusion.Population: AdultsPharmaStars (Egyptian pharmaceutical company)
• Prevention of recurrence of cerebral infarction (excluding cardiogenic cerebral embolism).Population: AdultsPharmaStars (Egyptian pharmaceutical company)
• Reduction of symptoms of intermittent claudication, as shown by increased walking distance.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (100 mg twice daily vs placebo): headache 34%, diarrhoea 19%, abnormal stools 15%, palpitation 10%, dizziness 10%, pharyngitis 10%, peripheral oedema 7%, rhinitis 7%, dyspepsia 6%, abdominal pain 5%, tachycardia 4%.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Heart failure of any severity (boxed warning: PDE3 inhibitors have decreased survival in class III-IV heart failure).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to cilostazol or any tablet component (e.g. anaphylaxis, angioedema).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• May induce tachycardia, palpitation, tachyarrhythmia or hypotension; patients with ischaemic heart disease may be at risk of angina exacerbation or myocardial infarction.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Left ventricular outflow tract obstruction has been reported in patients with sigmoid-shaped interventricular septum; monitor for a new systolic murmur or cardiac symptoms.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Thrombocytopenia or leukopenia progressing to agranulocytosis has been reported; avoid use in haemostatic disorders or active pathological bleeding.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Strong/moderate CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, diltiazem, grapefruit juice)Increase cilostazol exposure; reduce cilostazol to 50 mg twice daily.DailyMed (U.S. National Library of Medicine)
• CYP2C19 inhibitors (e.g. omeprazole)Increase exposure to active cilostazol metabolites; reduce cilostazol to 50 mg twice daily.DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; cilostazol was teratogenic in rats (cardiovascular, renal and skeletal anomalies) at exposures about 5 times the maximum recommended human dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Transfer into milk reported in rats; because of potential serious adverse reactions in nursing infants, discontinue nursing or discontinue cilostazol.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Cilostazol: Cilostazol and several metabolites inhibit phosphodiesterase III, increasing cAMP, which inhibits platelet aggregation reversibly and causes vasodilation.